Drug intelligence / Profile preview

USM119

Development stage: Preclinical
Lead developer: Uscare Pharm
Modality: Small Molecules
Administration: Implant

Overview

USM119 is a proprietary therapeutic candidate developed by Uscare Pharm, a biotechnology company focused on interventional medical materials and devices. It is categorized within the company's 'Material Innovation' pipeline, which encompasses advanced coatings and bioactive substances designed for vascular applications. USM119 is specifically indicated for vascular wall treatment, where it is likely utilized as a drug component or a bioactive coating for drug-eluting stents or balloons to prevent restenosis and facilitate vascular healing. As of 2024, the asset is in the clinical trial stage of development.

Beyond the preview

Go deeper on USM119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on USM119.

Explore the full profile